The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus

被引:56
|
作者
van der Leeuw, J. [1 ]
van Dieren, S. [2 ,3 ]
Beulens, J. W. J. [2 ]
Boeing, H. [4 ]
Spijkerman, A. M. W. [5 ]
van der Graaf, Y. [2 ]
van der A, D. L. [5 ]
Noethlings, U. [6 ]
Visseren, F. L. J. [1 ]
Rutten, G. E. H. M. [2 ]
Moons, K. G. M. [2 ]
van der Schouw, Y. T. [2 ]
Peelen, L. M. [2 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands
[4] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany
[5] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands
[6] Univ Bonn, Dept Nutr & Food Sci, Bonn, Germany
关键词
CORONARY-HEART-DISEASE; EXTERNAL VALIDATION; PREDICTION MODELS; VASCULAR-DISEASE; FRAMINGHAM; ENGINE; DERIVATION; EQUATIONS; EVENTS; PEOPLE;
D O I
10.1136/heartjnl-2014-306068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Various cardiovascular prediction models have been developed for patients with type 2 diabetes. Their predictive performance in new patients is mostly not investigated. This study aims to quantify the predictive performance of all cardiovascular prediction models developed specifically for diabetes patients. Design and methods Follow-up data of 453, 1174 and 584 type 2 diabetes patients without pre-existing cardiovascular disease (CVD) in the EPIC-NL, EPIC-Potsdam and Secondary Manifestations of ARTerial disease cohorts, respectively, were used to validate 10 prediction models to estimate risk of CVD or coronary heart disease (CHD). Discrimination was assessed by the c-statistic for time-to-event data. Calibration was assessed by calibration plots, the Hosmer-Lemeshow goodness-of-fit statistic and expected to observed ratios. Results There was a large variation in performance of CVD and CHD scores between different cohorts. Discrimination was moderate for all 10 prediction models, with c-statistics ranging from 0.54 (95% CI 0.46 to 0.63) to 0.76 (95% CI 0.67 to 0.84). Calibration of the original models was poor. After simple recalibration to the disease incidence of the target populations, predicted and observed risks were close. Expected to observed ratios of the recalibrated models ranged from 1.06 (95% CI 0.81 to 1.40) to 1.55 (95% CI 0.95 to 2.54), mainly driven by an overestimation of risk in high-risk patients. Conclusions All 10 evaluated models had a comparable and moderate discriminative ability. The recalibrated, but not the original, prediction models provided accurate risk estimates. These models can assist clinicians in identifying type 2 diabetes patients who are at low or high risk of developing CVD.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 50 条
  • [21] Cardiovascular risk assessment in type 2 diabetes mellitus
    Ebaa Al-Ozairi
    R. Jan-Willem Middelbeek
    Edward S. Horton
    Current Diabetes Reports, 2006, 6 (5)
  • [22] Type 2 diabetes mellitus is not a cardiovascular risk equivalent
    Saely, CH
    Marte, T
    Aczel, S
    Langer, P
    Koch, L
    Schmid, F
    Drexel, H
    DIABETES, 2005, 54 : A182 - A183
  • [23] Cardiovascular risk in the spectrum of type 2 diabetes mellitus
    Ahmed, Intekhab
    Goldstein, Barry J.
    MOUNT SINAI JOURNAL OF MEDICINE, 2006, 73 (05): : 759 - 768
  • [24] Risk factors for cardiovascular autonomic neuropathy in type 2 diabetes mellitus patients
    Semyatichko, E.
    Nemtsova, V.
    Feclina, I.
    JOURNAL OF NEUROLOGY, 2007, 254 : 110 - 110
  • [25] Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Budoff, Matthew J.
    Wilding, John P. H.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [26] Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus
    Cockcroft, JR
    Wilkinson, IB
    Evans, M
    McEwan, P
    Peters, JR
    Davies, S
    Scanlon, MF
    Currie, CJ
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (11) : 1463 - 1467
  • [27] Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
    Song, Do Kyeong
    Hong, Young Sun
    Sung, Yeon-Ah
    Lee, Hyejin
    PLOS ONE, 2024, 19 (02):
  • [28] CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH OR WITHOUT METABOLIC SYNDROME
    Millan, J.
    Garcia Calzado, C.
    Recarte, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 29 - 29
  • [29] Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
    Lorber, Daniel
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 169 - 183
  • [30] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181